PMID- 30658120
OWN - NLM
STAT- MEDLINE
DCOM- 20200618
LR  - 20200618
IS  - 1873-6815 (Electronic)
IS  - 0531-5565 (Linking)
VI  - 118
DP  - 2019 Apr
TI  - A novel neurocognitive approach for placebo analgesia in neurocognitive 
      disorders.
PG  - 106-116
LID - S0531-5565(18)30082-2 [pii]
LID - 10.1016/j.exger.2019.01.011 [doi]
AB  - Neural correlates of placebo analgesia (PA) in patients with neurocognitive 
      disorders have not yet been elucidated. The present study aimed to evaluate how 
      and to what extent executive (dys)functions of the medial prefrontal cortex 
      (MPFC) may be related to PA. To this end, twenty-three subjects complaining of 
      different cognitive deficits (from mild cognitive impairment likely due to 
      Alzheimer's disease to mild AD) were recruited. PA was investigated by a 
      well-known experimental venipuncture pain paradigm (open versus hidden [O-H] 
      application of lidocaine). Patients also underwent a comprehensive 
      neuropsychological evaluation and a functional magnetic resonance imaging (fMRI) 
      GO/No-GO task for eliciting selective activation of the MPFC. Selected 
      neuropsychological variables were correlated to the OH-PA paradigm. The 
      association between the fMRI response on the "No-GO" versus "GO" contrast and PA 
      was investigated over the whole-brain by regression analysis. We showed the 
      existence of a relationship between a lower PA and MPFC dysfunctions through the 
      neuropsychological and fMRI assessment. A separate voxel-based morphometry (VBM) 
      analysis controlled for possible influence of grey matter (GM) volume reduction 
      on both fMRI results and PA. fMRI results were not directly affected by, and 
      therefore independent of, disease-specific GM atrophy, which was indeed located 
      more anteriorly within the rostral anterior cingulate and inversely correlated 
      with PA. Our findings shed new light on the underestimated contribution of 
      executive (dys)functions mediated by the MPFC (response-inhibition, 
      self-monitoring and set-shifting abilities) in PA pathogenesis, with a special 
      purely (i.e. independently from brain structural alterations) functional role 
      played by the MCC. Results are discussed in terms of possible clinical relevance 
      in the management of patients with neurocognitive disorders.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Palermo, S
AU  - Palermo S
AD  - Department of Psychology, University of Turin, Italy. Electronic address: 
      sara.palermo@unito.it.
FAU - Rainero, I
AU  - Rainero I
AD  - Neurology 1st Unit, Department of Neuroscience "Rita Levi Montalcini", University 
      of Turin, Turin, Italy.
FAU - Stanziano, M
AU  - Stanziano M
AD  - Postgraduate School in Radiodiagnostics, University of Milan, Milan, Italy; Brain 
      Imaging Center, Neuroscience Institute of Turin (NIT), Turin, Italy.
FAU - Vase, L
AU  - Vase L
AD  - Department of Psychology and Behavioural Sciences, School of Business and Social 
      Sciences, Aarhus University, Aarhus, Denmark.
FAU - D'Agata, F
AU  - D'Agata F
AD  - Brain Imaging Center, Neuroscience Institute of Turin (NIT), Turin, Italy.
FAU - Rubino, E
AU  - Rubino E
AD  - Neurology 1st Unit, Department of Neuroscience "Rita Levi Montalcini", University 
      of Turin, Turin, Italy.
FAU - Fonio, P
AU  - Fonio P
AD  - Department of Diagnostic and Interventional Imaging, Radiology Institute, 
      University of Turin, A.O.U. "Citta della Salute e della Scienza di Torino", 
      Turin, Italy.
FAU - Sardanelli, F
AU  - Sardanelli F
AD  - Department of Biomedical Sciences for Health, University of Milan, San Donato 
      Milanese, Italy; IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
FAU - Amanzio, M
AU  - Amanzio M
AD  - Department of Psychology, University of Turin, Italy; European Innovation 
      Partnership on Active and Healthy Ageing, Brussels, Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190115
PL  - England
TA  - Exp Gerontol
JT  - Experimental gerontology
JID - 0047061
SB  - IM
MH  - Aged
MH  - Alzheimer Disease/physiopathology
MH  - Analgesia/*methods
MH  - Executive Function/physiology
MH  - Female
MH  - Gray Matter/pathology
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Neurocognitive Disorders/*physiopathology
MH  - Neuropsychological Tests
MH  - Pain Perception
MH  - Placebo Effect
MH  - Prefrontal Cortex/diagnostic imaging/physiology
OTO - NOTNLM
OT  - Anterior cingulate cortex
OT  - Executive functions
OT  - Neurocognitive disorders
OT  - Placebo analgesia
OT  - Response inhibition
OT  - fMRI
EDAT- 2019/01/19 06:00
MHDA- 2020/06/19 06:00
CRDT- 2019/01/19 06:00
PHST- 2018/02/05 00:00 [received]
PHST- 2018/12/24 00:00 [revised]
PHST- 2019/01/11 00:00 [accepted]
PHST- 2019/01/19 06:00 [pubmed]
PHST- 2020/06/19 06:00 [medline]
PHST- 2019/01/19 06:00 [entrez]
AID - S0531-5565(18)30082-2 [pii]
AID - 10.1016/j.exger.2019.01.011 [doi]
PST - ppublish
SO  - Exp Gerontol. 2019 Apr;118:106-116. doi: 10.1016/j.exger.2019.01.011. Epub 2019 
      Jan 15.